Ignite Creation Date:
2025-12-24 @ 5:48 PM
Ignite Modification Date:
2026-01-23 @ 2:57 PM
Study NCT ID:
NCT00968968
Status:
TERMINATED
Last Update Posted:
2019-06-10
First Post:
2009-08-27
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone
Sponsor:
Novartis Pharmaceuticals
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2010-01-20
Start Date Type:
ACTUAL
Primary Completion Date:
2014-02-21
Primary Completion Date Type:
ACTUAL
Completion Date:
2018-03-30
Completion Date Type:
ACTUAL
First Submit Date:
2009-08-27
First Submit QC Date:
None
Study First Post Date:
2009-08-31
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2019-03-19
Results First Submit QC Date:
None
Results First Post Date:
2019-06-10
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2019-06-05
Last Update Post Date:
2019-06-10
Last Update Post Date Type:
ACTUAL